Edward Zajac, MD
Interventional Cardiology · Sioux City, IANPI 1265406060
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,600 of the $27,149 with a category attached, or 75.9%. Pfizer accounts for 74.2% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $12,946 and has fallen 89.9% since, to $1,312 in 2025.
Across 157 payments — averaging $172.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$20K
- Medtronic$4K
- Boston Scientific$1K
- Boehringer Ingelheim$288
- Johnson & Johnson$226
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$175
- plus $1K from 17 others
What the payments were for
- Speaking & faculty fees$20,60076%
- Travel & lodging$2,81410%
- Food & beverage$3,69114%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 36 | $20,146 |
| Medtronic(2 entities) | 39 | $3,725 |
| Boston Scientific | 12 | $1,423 |
| Boehringer Ingelheim | 6 | $288 |
| Johnson & Johnson | 5 | $226 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $175 |
| AstraZeneca | 6 | $166 |
| E.r. Squibb & Sons, L.L.C. | 9 | $139 |
| Impulse Dynamics (USA) Inc. | 1 | $115 |
| Abbott | 5 | $106 |
| Amgen | 3 | $103 |
| Abiomed | 3 | $91 |
| Actelion Pharmaceuticals US, Inc. | 1 | $80 |
| Inari Medical, Inc. | 1 | $80 |
| Biosense Webster, Inc. | 3 | $79 |
| Novartis | 3 | $43 |
| Chiesi USA, Inc. | 2 | $35 |
| Cardiva Medical, Inc. | 1 | $33 |
| Biotronik Inc. | 2 | $30 |
| Penumbra, Inc. | 1 | $21 |
| Terumo Medical Corporation | 1 | $16 |
| Cardiovascular Systems Inc. | 1 | $15 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$19,563
- GENERAL - THERAPIES$1,036
- ONYX FRONTIER$1,032
- Micra$271
- OPTIMIZER$231
- JARDIANCE$226
- XARELTO$115
- Resolute$103
How this compares
$27,149 in reported general payments places this provider in the 80th percentile of 64 interventional cardiology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 39 | $25,498 |
| BrilintaTicagrelor | 23 | $15,855 |
| EliquisApixaban | 20 | $15,788 |
| XareltoRivaroxaban | 21 | $14,542 |
| JardianceEmpagliflozin | 17 | $9,315 |
| NexletolBempedoic Acid | 13 | $5,155 |
| Metoprolol Succinate | 59 | $340 |
| Atorvastatin Calcium | 61 | $319 |
| Carvedilol | 20 | $127 |
| Spironolactone | 17 | $97 |
| Rosuvastatin Calcium | 23 | $53 |
| ClopidogrelClopidogrel Bisulfate | 49 | $42 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 18 | $25 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $43 | $25,49839 claims |
| AstraZenecaBrilinta | $166 | $15,85523 claims |
| PfizerEliquis | $20,146 | $15,78820 claims |
| Johnson & JohnsonXarelto | $226 | $14,54221 claims |
| Boehringer IngelheimJardiance | $288 | $9,31517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 64 interventional cardiology providers in Iowa.
Other interventional cardiology in Sioux City
- Nabil BraitehSioux City$10K
- Khalid ChangalSioux City$7K
- Nicolas ShammasDavenport$808K
- Eric DippelDavenport$100K
- Atul ChawlaDes Moines$78K
- Magdi GhaliWest Des Moines$64K
- David McAllisterDes Moines$55K
- Daniel ShivapourDes Moines$54K
- Srikanth KasulaDavenport$43K
- Abdulrahman AbdulbakiDes Moines$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.